Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark I Furman

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Clinical Cardiology|May 20, 2008
Antiplatelet therapy and platelet function testingEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Investigating the mechanisms of hyporesponse to antiplatelet approachesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Journal of Vascular Surgery|February 4, 2003
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombinR Brannon Claytor, Alan D Michelson, Jian-Ming Li, et al.
Journal of Thrombosis and Thrombolysis|November 19, 2010
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndromeRichard C Becker, Kenneth W Mahaffey, Hongqiu Yang, et al.
American Heart Journal|March 30, 2002
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapyGuy L Wheeler, Gregory A Braden, Steven R Steinhubl, et al.
American Heart Journal|December 24, 2003
Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE)Mark I Furman, Joel M Gore, Fredrick A Anderson, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Clinical Cardiology|May 20, 2008
Antiplatelet therapy and platelet function testingEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Investigating the mechanisms of hyporesponse to antiplatelet approachesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Journal of Vascular Surgery|February 4, 2003
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombinR Brannon Claytor, Alan D Michelson, Jian-Ming Li, et al.
Journal of Thrombosis and Thrombolysis|November 19, 2010
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndromeRichard C Becker, Kenneth W Mahaffey, Hongqiu Yang, et al.
American Heart Journal|March 30, 2002
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapyGuy L Wheeler, Gregory A Braden, Steven R Steinhubl, et al.
American Heart Journal|December 24, 2003
Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE)Mark I Furman, Joel M Gore, Fredrick A Anderson, et al.
Pageof 4